Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway by Cubas, Rafael et al.
RESEARCH Open Access
Trop2 expression contributes to tumor
pathogenesis by activating the ERK MAPK
pathway
Rafael Cubas
1,2, Sheng Zhang
2, Min Li
2, Changyi Chen
2, Qizhi Yao
1,2*
Abstract
Background: Trop2 is a cell-surface glycoprotein overexpressed by a variety of epithelial carcinomas with reported
low to restricted expression in normal tissues. Expression of Trop2 has been associated with increased tumor
aggressiveness, metastasis and decreased patient survival, but the signaling mechanisms mediated by Trop2 are
still unknown. Here, we studied the effects murine Trop2 (mTrop2) exerted on tumor cellular functions and some
of the signaling mechanisms activated by this oncogene.
Results: mTrop2 expression significantly increased tumor cell proliferation at low serum concentration, migration,
foci formation and anchorage-independent growth. These in vitro characteristics translated to increased tumor
growth in both subcutaneous and orthotopic pancreatic cancer murine models and also led to increased liver
metastasis. mTrop2 expression also increased the levels of phosphorylated ERK1/2 mediating cell cycle progression
by increasing the levels of cyclin D1 and cyclin E as well as downregulating p27. The activation of ERK was also
observed in human pancreatic ductal epithelial cells and colorectal adenocarcinoma cells overexpressing human
Trop2.
Conclusions: These findings demonstrate some of the pathogenic effects mediated by mTrop2 expression on
cancer cells and the importance of targeting this cell surface glycoprotein. This study also provides the first
indication of a molecular signaling pathway activated by Trop2 which has important implications for cancer cell
growth and survival.
Background
Trop2 is a cell surface glycoprotein belonging to the
TACSTD gene family and highly overexpressed by a vari-
ety of epithelial carcinomas with low to restricted expres-
sion in normal tissues [1-6]. Clinical data has shown a
positive correlation between Trop2 expression levels and
tumor aggressiveness and metastasis, and a negative cor-
relation with overall patient survival [1-6]. Trop2 is
highly conserved among species with a 79% identical
amino acid composition between human and murine
Trop2. This protein was initially found to be highly
expressed in trophoblast cells, which arise from epithelial
trophectoderm cells and become invasive, phagocytosing
and displacing uterine epithelial cells. This allows for the
penetration of the uterine stroma in order to establish
vascular interactions with the maternal blood supply
[7,8]. Trop2 expression has also been observed in murine
and human prostate basal cells with stem cell characteris-
tics [9]. Basal stem progenitor cells with high Trop2
expression were shown to give rise to basal, luminal and
even neuroendocrine cells in vivo. A similar behavior has
also been reported in hepatic oval cells which are consid-
ered facultative hepatic stem cells and shown to express
Trop2 [10]. It thus appears that Trop2 provides crucial
signals for cells with a requirement for proliferation, sur-
vival and invasion such as trophoblast cells or cells with
progenitor-like characteristics. These same characteristics
might be conferred to cancer cells by overexpression of
this surface glycoprotein.
Trop2 has recently been identified as an oncogene
leading to the invasiveness and tumorigenesis of colon
cancer cells, but the underlying signaling mechanisms
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any medium, provided the original work is properly cited.activated by this protein are still unknown [11]. It has
been shown that cross-linking this protein with antibo-
dies results in a significant rise in intracellular calcium
[Ca
2+]f r o mi n t e r n a ls t o r e sw h i c hc o u l dh a v eas i g n i f i -
cant effect on the activation and progression of the cell
cycle as well as activation of other signaling pathways
[12-15]. The cytoplasmic tail of Trop2 appears to play
an important role in signaling. One study has shown the
presence of a phosphatidylinositol 4,5-bis phosphate
(PIP2)-binding sequence highly homologous to that of
gelsolin [16]. Within this sequence there is a conserved
serine residue which is phosphorylated by protein kinase
C (PKC) [17]. Thus, PKC and mitogen-activated protein
kinases (MAPKs) including ERK1/2 may be involved in
Trop2 induced tumor cell growth [17,18].
The purpose of this study was to determine the effects
of murine Trop2 expression (mTrop2) in cancer cells
and to start delineating the pathways activated by this
molecule. We found that mTrop2 expression resulted in
increased cell proliferation at low serum concentrations
with an increased percentage of cells entering S phase.
Expression of mTrop2 also led to increased cell migra-
tion, foci formation and anchorage independent growth
and translated to increased tumor growth in both sub-
cutaneous and orthotopic tumor models. mTrop2
expression also led to increased liver metastasis as well
as increased levels of phosphorylated p42/p44
MAPK
(ERK1/ERK2) which is a master regulator of the G1-t o
S-phase transition [18,19]. This translated to a rise in
cyclin D1 and cyclin E protein levels with a downregula-
tion of p27. This study provides new evidence that
Trop2 contributes to tumor pathogenesis at least in part
by activating the ERK1/2 MAPK pathway which has
important implications for a variety of cellular pathways
as it can affect cancer cell proliferation, migration, inva-
sion and survival [18,20-22].
Results
Expression of mTrop2 increases cell proliferation at low
serum concentrations
In order to elucidate whether mTrop2 expression has
any effect on the growth of cancer cells we generated
stable murine pancreatic adenocarcinoma cells (Panc02)
expressing mTrop2 (Panc02-mTrop2) since this cell line
does not naturally express this surface glycoprotein.
A control cell line expressing GFP (Panc02-GFP) was
also generated. To determine the function of mTrop2,
Panc02-GFP and the parental cell line Panc02 were used
as controls in all assays. As shown in Fig. 1A, stable
Panc02-mTrop2 cells express mTrop2 as determined by
real-time quantitative PCR and immunoblotting and this
expression is present on the cell surface as demon-
strated by flow cytometry using an anti-mTrop2
monoclonal antibody. All three cell lines were then used
in a proliferation assay to assess any difference in the
growth rate capabilities of these cells. The results
showed that Panc02-mTrop2 cells had a significant
increase in proliferation at low serum concentrations
when compared to normal Panc02 or Panc02-GFP cells
(P < 0.01; Fig. 1B). Panc02-mTrop2 cells proliferated 2.7
times faster than Panc02-GFP cells at day 5. It is impor-
tant to note that expression of mTrop2 did not appear
to affect proliferation at high serum concentrations and
this was only evident when low serum levels were used
(data not shown). To obtain a more comprehensive
understanding of the effect mTrop2 had on cell prolif-
eration, we examined the cell cycle progression of
Panc02, Panc02-GFP and Panc02-mTrop2 cells by pro-
pidium iodide staining and flow cytometry analysis. In
order to confirm that the effect on cell cycle progression
conferred by mTrop2 is not restricted to Panc02 cells,
but rather a generalized effect, we included stable GFP
(4T1-GFP) and mTrop2 expressing (4T1-mTrop2) mur-
ine breast cancer (4T1) and murine colorectal adenocar-
cinoma (MC38) cells (MC38-GFP and MC38-mTrop2).
As depicted in Fig. 1C, there was an increase in the per-
centage of cells entering S phase after releasing serum
starved cells with 2% serum-containing medium in all
cell lines expressing mTrop2. This increase in cells
entering S phase came with a reduction in the popula-
tion of cells in the G0/G1 phase. The percentage of cells
entering S phase in the mTrop2 group was 35% which
was about 10% (35% vs. 25%) and 15% (35% vs. 20%)
higher when compared to the Panc02 and Panc02-GFP
groups, respectively. A similar trend was also observed
in 4T1-mTrop2 and MC38-mTrop2 cells where there
was a significant increase in the percentage of cells
entering S phase when compared to the control cells.
These results demonstrate that mTrop2 expression leads
to increased cell growth by inducing a faster progression
into the synthesis phase of the cell cycle.
Expression of mTrop2 enhances cell migration, foci
formation and anchorage- independent growth
Increased migration is a characteristic of aggressive can-
cer cells. To determine whether mTrop2 expression
could result in increased cell migration, we performed a
monolayer wound healing assay. Panc02 cells are natu-
rally aggressive and tend to migrate at accelerated rates.
However, expression of mTrop2 resulted in a further
increase in the rate of migration when compared to the
parental and GFP control cell lines at both 0% and 5%
serum concentrations (P <0 . 0 0 0 1 )( F i g .2 A ) .I n5 %
serum conditions the induced wound was barely visible
in the Panc02-mTrop2 group after 24 hours. This
increase in migration was also observed in the absence
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sic ability to foster cell migration without the presence
of growth factors.
The generation of foci represents a loss of contact
inhibition or the ability to maintain cell growth and
movement despite contact with surrounding cells. To
determine whether ectopic expression of mTrop2 could
transform cells and confer loss of contact inhibition, we
transfected NIH3T3 cells with GFP- (NIH3T3-GFP) or
mTrop2- (NIH3T3-mTrop2) containing plasmids. These
cells were then allowed to grow in 6-well plates until
foci greater than 1 mm were apparent. As shown in
Figure 1 Expression of mTrop2 can promote cell proliferation and cell cycle progression. (a) Stable murine pancreatic adenocarcinoma
cells (Panc02) expressing either mTrop2 (Panc02-mTrop2) or GFP (Panc02-GFP) were generated. The increase in mTrop2 mRNA levels in Panc02-
mTrop2 cells was measured by quantitative real-time RT PCR. The y axis represents the normalized mTrop2 expression relative to b-actin
expression. The protein levels of mTrop2 were determined by Western blot analysis and its membrane incorporation by flow cytometry. (b)
Panc02-mTrop2 and control cells were seeded in 96-well plates (1 × 10
3 cells/well) and serum-starved for 24 h before changing to growth
medium containing 0.2% FBS. MTS assay was performed after breaking serum starvation. Relative increase in viability was measured by dividing
the viability at one time point by the viability of the same cell at day 0. Absorbance means ± SD (n = 5) are shown. *P < 0.01. (c) Cell cycle
analysis. After 24 h of serum starvation, cells were released by the addition of 2% FBS for 4 h (Panc02 and 4T1 cells) or 8 h (MC38 cells). Cells
were collected, fixed, stained with propidium iodide and analyzed for cell cycle phase distribution. Data shown is representative from three
independent experimental repeats.
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in the number of foci generated when compared to the
GFP control group (P < 0.0001). This shows that trans-
fection with a plasmid expressing mTrop2 is sufficient
to induce the transformation of NIH3T3 cells. This abil-
i t yo fm T r o p 2t oi n d u c ef o c if o r m a t i o nw a sa l s o
observed when mTrop2 was expressed in the more
indolent murine pancreatic adenocarcinoma cell line
Panc03 (Fig. 2C).
To further study the phenotypic changes conferred by
mTrop2 on cancer cells, we evaluated the ability of this
protein to increase the rate of soft agar colony forma-
tion on Panc02 cells. As shown in Fig. 2D, mTrop2
expression resulted in a 12.5-fold increase in the num-
ber of colonies formed at a very early time point. This
represents a significant change in the growth rate cap-
ability of these cells in soft agar and an ability to prolif-
erate under such stringent conditions. mTrop2 is thus
capable of increasing the proliferative capacity and
aggressiveness of tumor cells and might also be provid-
ing certain survival signals.
Expression of mTrop2 correlates with increased tumor
growth
We have shown that mTrop2 expression in tumor cells
can lead to an increase in cell proliferation, migration
Figure 2 Expression of mTrop2 leads to increased migration, foci formation and anchorage-independent growth. (a) Panc02-mTrop2
and control cells were serum starved for 24 h followed by the addition of media containing either 0% or 5% FBS. Wounds were generated in
confluent cell monolayers utilizing a sterile pipette tip. Pictures were taken 24 h after the wound insult. A representative field for each cell line is
shown. (b) The expression of mTrop2 led to a loss of contact inhibition and foci formation. Foci greater than 1 mm were counted after 16 days.
Mean ± SD is shown (n=3 ). ** P < 0.0001. (c) Expression of mTrop2 on the more indolent murine pancreatic adenocarcinoma cell line, Panc03,
also led to increased foci formation (arrows). (d) Panc02-mTrop2 cells acquire an enhanced ability to grow in soft agar. Panc02-mTrop2 and
control cells were plated in 6-well plates as described in the Methods section. Colonies were measured after 72 h to determine the increased
rate of colony formation in Panc02-mTrop2 cells. Results are shown as mean ± SD (n=3 ). *P < 0.001.
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to investigate the effects of mTrop2 expression in an
in vivo setting, we inoculated Panc02-GFP and Panc02-
mTrop2 cells subcutaneously into the left flank of
immunodeficient nude mice to compare their overall
growth rate. As observed in Fig. 3A, Panc02-mTrop2
cells showed a significant increase (3-fold) in tumor
growth over GFP control cells (P < 0.01). Since a subcu-
taneous setting differs from an orthotopic environment,
we wanted to confirm whether the observed increase in
tumor growth rate was also reproducible in more realis-
tic growth conditions and whether there was any effect
on the metastatic potential of these murine pancreatic
cancer cells. To achieve this, Panc02, Panc02-GFP or
Panc02-mTrop2 cells were inoculated into the tail of
the pancreas in immunodeficient mice. Tumors were
allowed to grow for 2 weeks at which point mice were
euthanized and the tumors extracted for further charac-
terization. As shown in Fig. 3B, mice inoculated with
Panc02-mTrop2 cells showed an 8.3- and 10-fold
increase in tumor weight with respect to mice inocu-
lated with control Panc02 or Panc02-GFP cells, respec-
tively (P < 0.01). The extensive difference in tumor size
can be visualized in Fig. 3B. Immunohistochemistry was
used to confirm the expression of mTrop2 in pancreatic
tumor tissues from mice inoculated with Panc02-
mTrop2 cells. The expression of mTrop2 correlated
with increased expression of the proliferation marker
Ki-67. One third of the mice from the Panc02-mTrop2
g r o u pa l s os h o w e di n d i c a t i o ns of liver metastasis (Fig.
3D-E). Further staining with Ki-67, PCNA and mTrop2
confirmed the presence of mTrop2 expressing tumor
cells inside the liver which also showed increased Ki-67
and PCNA expression (Fig. 3F). These results corrobo-
rate our in vitro data which shows that mTrop2 expres-
sion can increase the growth capacity and aggressiveness
of tumor cells.
mTrop2 expression increases activation of the ERK1/2
MAPK pathway
Little is known about the signaling pathways activated
by Trop2. Earlier work has shown that this protein
increases the level of intracellular calcium which could
potentially have an effect on a variety of proteins
involved in cell signaling mechanisms [12]. Other work
h a sd e m o n s t r a t e dt h a tt h ec y t oplasmic tail which con-
tains a conserved PIP2-binding motif and a serine resi-
due phosphorylated by protein kinase C (PKC) might be
essential for signaling [16,17]. The cytoplasmic tail for
both murine and human Trop2 is highly conserved with
an 84% sequence identity and only a three amino acid
difference (Fig. 4A). A similar degree of conservation is
also observed for different species alluding to the likely
importance the cytoplasmic tail has for signaling and
suggesting a maintenance of Trop2 functions through-
out different species. Despite these initial observations,
the mechanism of action for this protein is still
unknown.
The mitogen-activated protein kinase (MAPK) path-
ways can be activated by a variety of stimuli leading to
the activation of multiple programs like cell proliferation
and motility, differentiation, as well as survival and
apoptosis [21]. Due to the apparent involvement of
mTrop2 in cell growth and aggressiveness we wanted to
determine whether there was induction of MAPK signal-
ing. To test for the induction of MAPK pathways we
used an activator protein 1 (AP-1) secreted alkaline
phosphatase (SEAP) reporter assay as this transcription
factor lies downstream of MAPK activation. As shown
in Fig. 4B, 293T cells transfected with an AP-1 SEAP
reporter construct together with a lentiviral vector con-
taining the mTrop2 gene (pWPXLd-mTrop2) led to a
significant increase in SEAP release when compared to
the vector control group (pWPXLd) signifying the
induction of AP-1 transcription. After transfection and
at the time of the assay 293T cells transfected with the
mTrop2 expression construct showed a high level of
mTrop2 expression as demonstrated by flow cytometry
( F i g .4 B ) .T h e s er e s u l t si ndicate that expression of
mTrop2 can lead to the activation of MAPK signaling
which results in the induction of the AP-1 transcription
factor.
In our cell cycle analysis, we observed an increase in
the percentage of cells entering S phase. This transition
from G1- to S-phase is largely mediated by the sustained
activation of ERK1/2 during the late stages of the G1
phase [23]. This MAPK pathway can be further stimu-
l a t e db ya ni n c r e a s ei nC a
2+ and activated ERK can
increase AP-1 activity via induction of c-fos [24,25]. It is
therefore possible that the ERK MAPK pathway is impli-
cated in mTrop2 signaling. To determine whether
induction of the AP-1 transcription factor was mediated
preferentially by ERK and not JNK or p38 signaling, cell
lysates from 293T cells used in the AP-1 SEAP assays
were harvested and used for immunoblotting to detect
the levels of total and phosphorylated ERK1/2. As
shown in Fig. 4C, 293T cells transfected with the
mTrop2 expression construct showed a higher level of
phosphorylated ERK when compared to the vector and
pSH-1 SEAP control cell lysates. To corroborate that
the change in SEAP activity mediated by AP-1 and
observed in 293T cells expressing mTrop2 was due to
ERK signaling, cells were treated with different concen-
trations of the MEK1 inhibitor PD98059 which lies
upstream of ERK. As observed in Fig. 4D, increasing
concentrations of PD98059 led to a reduction in AP-1
mediated SEAP release confirming the involvement of
ERK singling in the induction of AP-1 transcription
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SEAP release were not due to cell cytotoxicity as cell
viability was not affected by the different concentrations
of PD98059 used (data not shown).
To continue investigating the activation of ERK signal-
ing by mTrop2 expression, we examined the levels of
phosphorylated ERK1/2 in Panc02, Panc02-GFP and
Panc02-mTrop2 cells and found that the phosphorylated
levels of ERK1/2 were significantly higher in Panc02-
mTrop2 cells (Fig. 5A). The levels of cyclin D1 and
cyclin E were also significantly increased in both
Panc02-mTrop2 cells and Panc02-mTrop2 tumors as
Figure 3 mTrop2 expression increases tumorigenesis in subcutaneous and orthotopic tumor models.( a )N u / n um i c ew e r ei n o c u l a t e d
subcutaneously with 2 × 10
5 Panc02-GFP or Panc02-mTrop2 cells. Tumor size was monitored for 22 days with digital calipers and volumes
reported as mean ± SE (n = 5). *P < 0.01. (b) For the orthotopic model, nude mice were inoculated with 5 × 10
4 Panc02, Panc02-GFP or Panc02-
mTrop2 cells in the pancreas. Mice were monitored daily and euthanized after 14 days; data are reported as mean ± SD (n = 6). *P < 0.01. (c)
Expression of mTrop2 led to an increase in tumor size and cell proliferation. Immunohistochemistry of paraffin embedded tumor tissues show
expression of mTrop2 and Ki-67. (d) Panc02-mTrop2 cell inoculation results in liver metastasis as depicted in the square and blow out picture. (e)
H&E staining shows normal liver cell structure in Panc02 and Panc02-GFP inoculated mice and liver metastasis with aberrant liver cell structure in
Panc02-mTrop2 inoculated mice (10× low magnification and 40× high magnification) (f) Immunohistochemistry for Ki-67, PCNA and mTrop2 in
livers from Panc02 (A-C), Panc02-GFP (D-F) and Panc02-mTrop2 (G-I at 10× and J-L at 20× magnification) inoculated mice. All images shown are
representative of group.
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istry (Fig. 5B, C). These two molecules are downstream
targets of the ERK MAPK pathway and are involved in
the termination of the G0-G1 cell cycle arrest and initia-
tion and progression of the S phase. CDK2, which inter-
acts with cyclin E during the initiation and progression
of the S phase, was also increased in Panc02-mTrop2
cells. This increase was not observed for CDK4 one of
the CDKs which interacts with cyclin D (Fig. 5B). The
level of the CDK inhibitor p27, which acts as an inhibi-
tor of cell proliferation, was also decreased in Panc02-
mTrop2 cells (Fig. 5B).
We also wanted to confirm whether this activation of
ERK could be observed in a human pancreatic ductal
epithelial cell line (HPDE) overexpressing human Trop2
(hTrop2) since pancreatic adenocarcinoma, which repre-
sents 95% of pancreatic cancers, is thought to arise from
mutations in pancreatic ductal epithelial cells [26].
A human colorectal cancer cell line (HCT-116) overex-
pressing hTrop2 was also included. As shown in Fig.
5D, overexpression of hTrop2 in these cell lines led to
an increase in the phosphorylated levels of ERK1/2.
These results indicate that the ERK signaling pathway is
indeed activated by Trop2. Whether the activation of
Figure 4 Trop2 is highly conserved among species and mTrop2 expression can stimulate the AP-1 transcription factor.( a )T h e
percentage of sequence identity between the human and murine cytoplasmic tail of Trop2 is 84%. A similar conservation level is observed
among other species. “+” indicates a.a. difference. (b) Expression of mTrop2 leads to activation of the AP-1 transcription factor. 293T cells were
transiently co-transfected with an AP-1 SEAP reporter construct together with a vector control (pWPXLd) or mTrop2 expressing vector (pWPXLd-
mTrop2). As a positive control a pSH-1 SEAP construct was used. Media was collected and processed for SEAP assays and a representative result
from three separate experiments done in triplicate is shown as mean ± SD. The negative control was assigned a value of 1, and the other data
was normalized to this value. At the time of media collection co-transfected 293T cells show a high level of mTrop2 expression as shown by
flow cytometry. (c) Cell lysate from transfected 293T cells used in the AP-1 SEAP assay was harvested and used for immunoblotting to detect the
levels of total and phosphorylated ERK1/2. (d) 293T cells were transiently co-transfected with an AP-1 SEAP reporter construct together with
pWPXLd or pWPXLd-mTrop2. Cells were subsequently treated with media containing different concentrations of the MEK1 inhibitor PD98059 or
DMSO. Media was collected and processed for SEAP assays. Results are shown as mean ± SD.
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in intracellular calcium or directly through protein
interactions via the cytoplasmic tail still needs to be
elucidated.
Discussion
In the current study, we used murine Trop2 to investi-
gate the effects of its expression on murine pancreatic
cancer cell proliferation and tumor growth. We showed
that mTrop2 expression in the murine pancreatic cancer
line (Panc02) led to an increased number of cells enter-
ing S phase which resulted in increased cell growth at
low serum concentrations. Similarly, there was an
enhanced ability of cells expressing mTrop2 to migrate
even without the presence of serum in the media. This
low requirement for serum might be indicative that
Trop2 transduces a survival signal in a growth-factor
independent manner. Trop2 expression also led to foci
formation in NIH3T3 cells showing that expression of
this protein can lead to a loss of contact inhibition.
Further evidence for the role of mTrop2 in cell prolif-
eration and/or survival was observed in the improved
ability of Panc02 cells to form colonies in soft agar.
Panc02 cells normally form colonies in soft agar, but
expression of mTrop2 increased the rate of colony for-
mation and by day 3 there were already on average 25
Figure 5 mTrop2 expression stimulates the ERK MAPK pathway. (a) Subconfluent cells were used to prepare cell lysates and 60 μgo f
protein were used for immunoblotting using antibodies against phosphorylated and total ERK. (b) ERK downstream targets like cyclin E, cyclin
D1 and CDK2 show increased expression in mTrop2 expressing cells while p27 is downregulated. (c) Increased expression of cyclin D1 and cyclin
E was also observed in tumor tissues from mice inoculated with Panc02-mTrop2 cells, when compared to control Panc02 or Panc02-GFP tumor
tissues. Images shown are representative of group. (d) Cell lysates from stable human colorectal cancer (HCT-116) and human pancreatic ductal
epithelial (HPDE) cells overexpressing human Trop2 were also used for the detection of activated ERK. Increase in hTrop2 mRNA level in HCT-116
and HPDE cells was measured by quantitative real-time RT PCR. The y axis represents the normalized hTrop2 expression relative to b-actin
expression.
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group and these colonies did not arise from cell clump-
ing. Such in vitro characteristics were further main-
tained in subcutaneous and orthotopic tumor models
where Panc02-mTrop2 cells led to a significant increase
in tumor growth and metastatic rate. It is therefore evi-
dent that mTrop2 increases the growth, aggressiveness
and possibly survival signals inside the cell.
By using an AP-1 SEAP reporter assay as well as cell
lysates from control and mTrop2 expressing cells, we
were able to delineate an initial signaling pathway acti-
vated by mTrop2. mTrop2 expressing cells showed an
increase in the levels of phosphorylated ERK1/2 suggest-
ing an activation of this MAPK pathway. Cell division is
a complex process involving an intricate network of reg-
ulatory pathways [18]. One of these regulatory pathways
is the ERK1/2 mitogen-activated protein kinase pathway
which transduces extracellular signals into intracellular
responses and is necessary for G1- to S-phase transition.
This MAPK pathway can be activated by a variety of sti-
muli including mitogens, cytokines, and growth factors
which induce a transient rise in intracellular calcium
[Ca
2+] from both internal and external stores. The
cross-linking of Trop2 has previously been shown by
others to result in a significant rise in cytoplasmic cal-
cium [Ca
2+] and this could in turn be activating the
MAPK pathway through activation of PKC and/or Ca
2
+/calmodulin-dependent protein kinase II (CaMKII),
both of which can modulate the ERK pathway
[12,27,28]. These two proteins are activated by an
increase in Ca
2+ and CaMKII can bind and phosphory-
late MEK1 leading to the activation of ERK [27,29]. The
link between Trop2-induced calcium increase and acti-
vation of the ERK1/2 MAPK pathway has yet to be
established.
It is important to note that downstream activation of
AP-1 can be mediated not only by ERK activation, but
also by JNK or p38 MAPKs [30]. In this study we only
focused on ERK activation due to the observed changes
on cell growth and cell cycle progression observed fol-
lowing mTrop2 expression as well as the preferential
involvement of ERK in the AP-1 SEAP assays. However,
it is possible that crosstalk with the other MAPK path-
ways is taking place upstream of AP-1 as this transcrip-
tion factor serves as a connecting node, linking various
signal transduction pathways [31]. Trop2 could therefore
be affecting other MAPK pathways to some degree.
Nonetheless, ERK signaling can activate AP-1 which can
play an important role in cell proliferation, apoptosis,
differentiation, cancer cell invasion and has been shown
to regulate cyclin D1 and E2F in breast cancer cells [31].
Upon phosphorylation of the activation loop residues
of p44/p42 by MEK2, there is subsequent activation of
downstream targets which include transcription factors
and genes important for the cell cycle such as cyclin D
and cyclin E [32]. In the current study, an increase in
cyclin D1 and cyclin E expression was indeed observed
in Panc02 cells expressing mTrop2. Cyclin D1 partners
with CDK4 and CDK6 in the early to mid-G1 phase to
phosphorylate and inactivate the retinoblastoma protein
(pRB). The inactivation of pRB is also mediated by the
cooperation of cyclin E/CDK2 both of which showed
increased expression in mTrop2 expressing cells. Cyclin
D1 and cyclin E are both key regulators of the G1-t oS -
phase transition and have been implicated with tumori-
genesis and metastasis [33,34]. The cyclin-dependent
kinase inhibitor 1B, also known as p27, which binds to
and prevents the activation of cyclin D1-CDK4 or cyclin
E-CDK2 complexes, was also downregulated in mTrop2
expressing cells corroborating a progression of the cell
cycle [35].
Apart from a role in cell-cycle progression cyclin D1
could also be providing additional signals independent
of CDK4/6 which are also implicated in tumorigenesis
such as interaction with both FOXO1 and FOXO3a to
inhibit anoikis [33]. This inhibition could allow cells not
only to survive and proliferate, but also to metastasize
in the absence of an extracellular matrix support, some-
thing that was observed in our anchorage-independent
growth assay and orthotopic murine model where
Panc02-mTrop2 cells showed an improved capacity for
anchorage-independent growth and an increased meta-
static potential [36]. Heightened ERK activity could also
induce the phosphorylation of FOXO3a at residues
S294, S344 and S425 promoting its cytoplasmic localiza-
tion and proteasomal degradation following ubiquitina-
tion by MDM2 [37]. This interaction between the ERK
pathway and FOXO3a has been shown to promote cell
growth and tumorigenesis, but whether Trop2 induced
activation of ERK results in FOXO3a degradation still
needs to be determined [38]. Activation of ERK1/2
could also be providing anti-apoptotic signals thus pro-
moting the survival of tumor cells [20,39].
The majority of the experiments presented here
focused on the use of the murine pancreatic cancer cell
line Panc02 and expression of the murine homolog of
Trop2. Even though Trop2 is highly conserved among
species and similarities between murine and human
Trop2 suggest a conservation of protein structure and a
conservation of intracellular signaling, there is a possibi-
lity that murine and human Trop2 might induce differ-
ent effects in murine and human cancer cells
respectively. It is therefore important to confirm the
results presented here in multiple human pancreatic
cancer cell lines expressing human Trop2.
It is evident that Trop2 expression increases the level
of phosphorylated ERK1/2 which has downstream
effects on various cellular functions. Inhibition of this
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growth. Targeting this MAPK pathway with the use of
chemical inhibitors could potentially be used as a way
to counteract at least some of the oncogenic effects
mediated by this cell-surface glycoprotein and poten-
tially affect Trop2 expressing tumor cells at metastatic
sites. Inhibitors of the ERK pathway have already
entered clinical trials as potential therapeutic agents, but
ERK inhibitors can block a number of signals upstream
of ERK [40,41]. In the case of pancreatic cancer, more
than 90% of pancreatic adenocarcinomas show muta-
tions in the KRAS gene which result in constitutively
active Ras, which can affect the activation of the ERK
MAPK pathway [42-44]. Therefore targeting ERK in
pancreatic cancer patients will not specifically block sig-
nals from Trop2, but would rather block a number of
signals which result in the activation of ERK such as
those induced by KRAS mutations. The use of ERK inhi-
bitors in pancreatic cancer patients could therefore have
no specific association with Trop2 and a specific inhibi-
tor targeting Trop2 mediated signals would be highly
desirable and could potentially augment the effects of
ERK MAPK pathway inhibitors like PD0325901 and
AZD6244 on pancreatic cancer cells. Further investiga-
tion into the signaling mechanisms and protein interac-
tions mediated by Trop2 could lead to a better
understanding of the important role this protein plays in
cancerous cells. Precise protein interactions with its
cytoplasmic tail as well as interactions with its extracel-
lular region and studies aimed at determining the ligand
for Trop2 could aid in the development of compounds
specifically targeting Trop2 functions. The association of
this molecule with prostate and hepatic oval cells dis-
playing stem-cell characteristics hints to the possibility
that Trop2 could potentially be present and used as a
marker for cancer stem cells as has recently been
reported for human prostate cancer [45]. Whether
Trop2 plays a role in deregulating characteristic stem
cell proliferation and differentiation pathways such as
Notch, hedgehog and Wnt deserves further attention. If
Trop2 is indeed expressed by cancer stem cells, target-
ing and thoroughly understanding the mechanistic path-
ways affected by this molecule becomes of further
importance.
Conclusions
In this study we show that mTrop2 expression results in
increased tumor cell growth, apparent aggressiveness
and metastatic potential. Expression of this cell surface
glycoprotein also led to activation of the ERK MAPK
pathway promoting cell cycle progression by increasing
the levels of cyclin D1 and cyclin E in the murine pan-
creatic adenocarcinoma cell line Panc02. Activation of
the ERK MAPK pathway has important implications not
only for tumor growth, but via cross-talk with other sig-
naling pathways and molecules could be involved in
invasion, metastasis and survival. The overall behavior
of Trop2 could also be affected by the specific cancer
cell line used such that future experiments should focus
on a panel of cell lines from different types of cancer.
Hopefully this study will incite additional research on
this highly important molecule so that we can soon
have a more thorough understanding of the pathways
affected by this cell-surface glycoprotein which could
translate into the development of novel therapeutics
that could be used against a variety of epithelial cancers
overexpressing Trop2.
Methods
Cell culture and antibodies
Panc02 murine pancreatic adenocarcinoma cells were
originally established by Corbett et al. by implanting
cotton threads into the pancreas of C57BL/6 mice
which were impregnated with 3-methylcholanthrene
[46]. These cells were a kind gift from Dr. Sabry el-Nag-
gar (Medical University of South Carolina) and were
maintained in DMEM supplemented with 5% fetal
bovine serum (FBS) (HyClone), 100 U/ml penicillin and
100 μg/ml streptomycin (Gibco). NIH3T3 and 4T1 cells
were a kind gift from Dr. Paul Ling and Dr. Adrian Lee
(Baylor College of Medicine) and were maintained in
DMEM supplemented with 10% FBS, 100 U/ml penicil-
lin and 100 μg/ml streptomycin (complete DMEM).
MC38 murine colorectal adenocarcinoma cells were a
kind gift from Dr. John C. Morris (National Cancer
Institute). These cells were maintained in RPMI 1640
medium supplemented with 10% FBS, 100 U/ml penicil-
lin and 100 μg/ml streptomycin. Cells were grown at 37°
Ci n5 %C O 2. The human colonic epithelial cell line
HCT-116 was obtained from ATCC (CCL-247) and
maintained in complete DMEM media. Human pancrea-
tic ductal epithelial cells (HPDE) previously described by
Furukawa et al. were maintained in keratinocyte serum-
free (KSF) medium supplemented with bovine pituitary
extract and epidermal growth factor (Gibco) [47].
The following antibodies and dilutions were used:
anti-p44/42 MAPK (Thr202/Tyr204) 1:1000 (Cell Sig-
naling, 9101), anti-cyclin D1 1:500 (Santa Cruz, sc-
20044), anti-p27 1:1000 (Cell Signaling, 2552), anti-
CDK2 1:1000 (Cell Signaling, 2546), anti-CDK4 1:1000
(Cell Signaling, 2906), anti-cyclin E 1:500 (Upstate Cell
Signaling Solutions, 07-687), goat anti-rabbit IgG, HRP-
linked 1:2000 (Cell Signaling, 7074) and goat anti-mouse
IgG, HRP-linked 1:2000 (Cell Signaling, 7076).
Stable cell lines
To generate stable Panc02 cells expressing mTrop2, full-
length mTrop2 cDNA (BC117720) was cloned into the
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ing the mTrop2 gene was generated by cotransfecting
the 2
nd generation packaging vector psPAX2 (Addgene),
t h ee n v e l o p ec o n t a i n i n gp lasmid pMD2.G (Addgene)
and pWPXLd-mTrop2 into 293FT cells. For control len-
tivirus normal pWPXLd was utilized. Viral supernatants
were collected, filtered, concentrated and used to infect
Panc02 cells. Cells were selected based on their expres-
sion of mTrop2 or eGFP as measured by real-time RT-
PCR, immunoblotting and flow cytometry. This proce-
dure was used for the other murine cell lines as well
(4T1 and MC38).
For the generation of stable HCT-116 and HPDE cells
overexpressing human Trop2 (hTrop2) a pBabe-hTrop2
vector was utilized. This vector was a kind gift from Dr.
Loren Michel (Washington University School of Medi-
cine). Retrovirus harboring either the pBabe or pBabe-
hTrop2 constructs were generated and used for the
infection of cells followed by selection with puromycin.
Immunohistochemistry
For immunohistochemical staining tumor and liver tis-
sue samples were extracted and fixed overnight in for-
malin. The next day samples were washed in 70%
ethanol and embedded in paraffin. Sections (5 μm) were
then cut and mounted onto glass slides followed by
overnight incubation at 55°C. The tissues were then
deparaffinized and rehydrated with xylene and graded
alcohol series. Antigen retrieval was performed by using
10 mM sodium citrate buffer (pH 6) for 20 min. Endo-
genous peroxidases were quenched by incubating slides
for 20 min in methanol containing 30% hydrogen perox-
ide. Samples were then blocked for 1 hr followed by
overnight incubation of primary antibodies at 4°C. The
antibody dilutions used were: anti-murine Trop2 1:40
(R&D Systems, AF1122), anti-Ki-67 1:1000 (Novacastra,
United Kingdom), anti-PCNA 1:500 (Santa Cruz, sc-
7907), anti-cyclin D1 1:500 (Santa Cruz, sc-20044) and
anti-cyclin E 1:500 (Upstate Cell Signaling Solutions,
07-687). Slides were then washed in PBS followed by
incubation with biotinylated secondary antibodies for 30
min. Stain was visualized by incubating slides for
30 min with ABC reagent followed by diaminobenzidine
(DAB) treatment for 2-5 min (Vector Laboratories).
SEAP reporter assay
Partially confluent 293T cells (70-80%) were co-trans-
fected with 200 ng of AP-1 secreted alkaline phospha-
tase (SEAP) reporter gene plasmid DNA (pAP-1 SEAP),
500 ng of expression vector DNA (pWPXLd, pWPXLd-
mTrop2) or positive control vector (pSH-1 SEAP) with
Fugene HD transfection reagent (Roche) in 24-well
plates. After 24 hours media was removed and serum-
free media added to each well. The next day media was
collected and assayed for SEAP activity using a FLUOs-
tar Optima fluorescence plate reader (BMG Labtech).
Proliferation assays
For the proliferation assay, 2000 cells/well were seeded
in flat-bottom 96-well plates in complete DMEM con-
taining 5% FBS. The next day, cells were serum-starved
for 24 h followed by the addition of 0.2% FBS. Cells
were cultured for 3 or 5 days, at which point 20 μlo f
3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega,
Madison, WI) was added to each well and incubated at
37°C for 1.5 h. Absorbance was recorded at 490 nm
with an EL-800 universal microplate reader (Bio-Tek
Instruments, Winooski, VT).
For the proliferation assay in the presence of the
MEK1 inhibitor PD98059 (Calbiochem, San Diego, CA),
serum starvation was released by the addition of DMEM
containing 0.2% FBS and PD98059 (1 μM) for 4 h. After
incubation cells were carefully washed twice and kept in
DMEM with 0.2% FBS. Cells were cultured for 3 days
followed by MTS analysis.
Cell cycle analysis
Cells were serum-starved for 24 h followed by the addi-
tion of media containing 2% serum and collected after 4
or 8 h. Cells were harvested and processed using the
CycleTEST PLUS DNA reagent kit (Becton Dickinson,
Franklin Lakes, NJ) following the manufacturer’s
instructions. Briefly, cells were washed three times with
buffer containing sodium citrate, DMSO and sucrose.
Cells were subsequently incubated for 10 min each in
solution A (enzymatic digestion of cell membranes and
cytoskeletons), solution B (inhibit trypsin activity and
digest RNA) and solution C (stoichiometric binding of
propidium iodide to DNA at a final concentration of
125 ug/ml). Cells were analyzed by flow cytometry using
a FACSCalibur (Becton Dickinson) and FlowJo ver. 7.2.1
(Tree Star, Ashland, OR).
Wound healing assay
Wounds were generated in confluent cell monolayers
grown in 6-well plates with media containing either 0%
or 5% FBS using a sterile pipette tip. Healing was
o b s e r v e da t0 ,2 4 ,a n d4 8ha l o n gt h es c r a p el i n ea n da
representative field for each cell line was photographed.
Focus formation assay
NIH3T3 cells were plated at 5 × 10
5 cells/well in a
6-well plate. Cells were transfected with 1 μgo f
pWPXLd or pWPXLd-mTrop2 using Lipofectamine
2000 (Invitrogen, Carlsbad, CA). NIH-3T3 cells expres-
sing mTrop2 or GFP were then seeded in triplicate at
1×1 0
5 cells/well in a 6-well plate. Cells were allowed
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meter larger than 1 mm appeared. Cells were then
washed twice and foci counted.
Soft agar assay
At o t a lo f1 0
4 Panc02-GFP, Panc02-mTrop2 cells were
plated in triplicate in 6-well plates with 2 ml of growth
medium containing 0.35% agar and used to overlay 4 ml
layers of growth medium containing 0.7% agar. Colonies
with a diameter greater than 0.2 mm were counted
using a dissecting microscope.
Mouse models
Subconfluent and stable Panc02-GFP and Panc02-
mTrop2 cells were harvested and resuspended in
DMEM. For the orthotopic murine model, Panc02 cells
were also used. For the subcutaneous (s.c.) tumor
model, 2 × 10
5 cells were inoculated into the right flank
of 7- to 8-week-old female nude mice (National Cancer
Institute-Charles River). For the orthotopic tumor
model, 5 × 10
4 cells were injected into the pancreas of
7- to 8-week-old female nude mice. For intrapancreatic
injection, mice were anesthetized with 2.5% Avertin and
an incision of 1-cm was made in the left subcostal
region. The spleen was exteriorized and tumor cells in a
volume of 50 μl were injected into the pancreas. For the
s.c. tumor model, tumor size was measured twice weekly
using digital calipers and the tumor volume was calcu-
lated with the formula: tumor volume (mm
3)=[ l e n g t h
(mm)] × [width (mm)]
2 × 0.52. For the orthotopic
tumor model, mice were euthanized after 14 days.
Tumors were extracted and weighed. All experiments
were performed according to protocols approved by the
Institutional Animal Care and Use Committee at Baylor
College of Medicine.
Statistical analysis
Quantitative results are shown as mean ± SD. Statistical
analysis was done using Student’s t tests for paired data
between the control and mTrop2 groups or one-way
ANOVA to determine significant difference between
groups. P < 0.05 was considered significant.
Acknowledgements
This study was partially supported by the Michael E. DeBakey Department of
Surgery, Baylor College of Medicine, and MacDonald Fund from the St.
Luke’s hospital (to Q. Yao). Authors would like to thank Dr. Uddalak
Bharadwaj for his valuable discussion and advice.
Author details
1Department of Molecular Virology and Microbiology, Baylor College of
Medicine, One Baylor Plaza, Houston, TX 77030, USA.
2Molecular Surgeon
Research Center, Michael E. DeBakey Department of Surgery, Baylor College
of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Authors’ contributions
RC performed cell line generation, western blotting, proliferation assays, cell
cycle analysis, wound healing assay, focus formation assay, flow cytometry,
soft agar assay, AP-1 SEAP assays, immunohistochemistry, subcutaneous and
orthotopic mouse models and drafted manuscript. SZ helped in the
subcutaneous and orthotopic models. ML and CC participated in discussion.
QY participated in discussion and manuscript preparation and provided
grant support for this study. All authors read and approved the final version
of this manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 March 2010 Accepted: 21 September 2010
Published: 21 September 2010
References
1. Cubas R, Li M, Chen C, Yao Q: Trop2: A possible therapeutic target for
late stage epithelial carcinomas. Biochim Biophys Acta 2009,
1796(2):309-14, Epub 2009 Aug 14.
2. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G,
Spizzo G: High expression of TROP2 correlates with poor prognosis in
pancreatic cancer. Br J Cancer 2008, 99:1290-5.
3. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S,
Rasse M, Laimer K: TROP2: a novel prognostic marker in squamous cell
carcinoma of the oral cavity. Mod Pathol 2008, 21:186-91.
4. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G,
Muller HM, Margreiter R, Ofner D, et al: TROP2 expression as prognostic
marker for gastric carcinoma. J Clin Pathol 2009, 62:152-8.
5. Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S,
Matsubara H, Nomura F, Takiguchi M, Hiwasa T: Serological identification
of TROP2 by recombinant cDNA expression cloning using sera of
patients with esophageal squamous cell carcinoma. Int J Cancer 2004,
112:1029-35.
6. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M: Clinical
significance of TROP2 expression in colorectal cancer. Clin Cancer Res
2006, 12:3057-63.
7. Sutherland A: Mechanisms of implantation in the mouse: differentiation
and functional importance of trophoblast giant cell behavior. Dev Biol
2003, 258:241-51.
8. Lipinski M, Parks DR, Rouse RV, Herzenberg LA: Human trophoblast cell-
surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci
USA 1981, 78:5147-50.
9. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON: Trop2
identifies a subpopulation of murine and human prostate basal cells
with stem cell characteristics. Proc Natl Acad Sci USA 2008, 105:20882-7.
10. Okabe M, Tsukahara Y, Tanaka M, Suzuki K, Saito S, Kamiya Y, Tsujimura T,
Nakamura K, Miyajima A: Potential hepatic stem cells reside in EpCAM+
cells of normal and injured mouse liver. Development 2009, 136:1951-60.
11. Wang J, Day R, Dong Y, Weintraub SJ, Michel L: Identification of Trop-2 as
an oncogene and an attractive therapeutic target in colon cancers. Mol
Cancer Ther 2008, 7:280-5.
12. Ripani E, Sacchetti A, Corda D, Alberti S: Human Trop-2 is a tumor-
associated calcium signal transducer. Int J Cancer 1998, 76:671-6.
13. Cheng G, Liu BF, Yu Y, Diglio C, Kuo TH: The exit from G(0) into the cell
cycle requires and is controlled by sarco(endo)plasmic reticulum Ca2+
pump. Arch Biochem Biophys 1996, 329:65-72.
14. Takuwa N, Zhou W, Kumada M, Takuwa Y: Involvement of intact inositol-
1,4,5-trisphosphate-sensitive Ca2+ stores in cell cycle progression at the
G1/S boundary in serum-stimulated human fibroblasts. FEBS Lett 1995,
360:173-6.
15. Whitaker M, Larman MG: Calcium and mitosis. Semin Cell Dev Biol 2001,
12:53-8.
16. El Sewedy T, Fornaro M, Alberti S: Cloning of the murine TROP2 gene:
conservation of a PIP2-binding sequence in the cytoplasmic domain of
TROP-2. Int J Cancer 1998, 75:324-30.
17. Basu A, Goldenberg DM, Stein R: The epithelial/carcinoma antigen EGP-1,
recognized by monoclonal antibody RS7-3G11, is phosphorylated on
serine 303. Int J Cancer 1995, 62:472-9.
Cubas et al. Molecular Cancer 2010, 9:253
http://www.molecular-cancer.com/content/9/1/253
Page 12 of 1318. Meloche S, Pouyssegur J: The ERK1/2 mitogen-activated protein kinase
pathway as a master regulator of the G1- to S-phase transition.
Oncogene 2007, 26:3227-39.
19. Brondello JM, McKenzie FR, Sun H, Tonks NK, Pouyssegur J: Constitutive
MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene
transcription and S-phase entry in fibroblasts. Oncogene 1995,
10:1895-904.
20. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N: MEK/ERK
signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1
and promotes survival of human pancreatic cancer cells. J Cell Biochem
2000, 79:355-69.
21. Roux PP, Blenis J: ERK and p38 MAPK-activated protein kinases: a family
of protein kinases with diverse biological functions. Microbiol Mol Biol Rev
2004, 68:320-44.
22. Kim EK, Choi EJ: Pathological roles of MAPK signaling pathways in
human diseases. Biochim Biophys Acta 1802:396-405.
23. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E:
Continuous ERK activation downregulates antiproliferative genes
throughout G1 phase to allow cell-cycle progression. Curr Biol 2006,
16:1171-82.
24. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A,
Vanderbilt C, Cobb MH: MAP kinases. Chem Rev 2001, 101:2449-76.
25. Rosen LB, Ginty DD, Weber MJ, Greenberg ME: Membrane depolarization
and calcium influx stimulate MEK and MAP kinase via activation of Ras.
Neuron 1994, 12:1207-21.
26. Grapin-Botton A: Ductal cells of the pancreas. Int J Biochem Cell Biol 2005,
37:504-10.
27. Li N, Wang C, Wu Y, Liu X, Cao X: Ca(2+)/calmodulin-dependent protein
kinase II promotes cell cycle progression by directly activating MEK1
and subsequently modulating p27 phosphorylation. J Biol Chem 2009,
284:3021-7.
28. Brandlin I, Hubner S, Eiseler T, Martinez-Moya M, Horschinek A, Hausser A,
Link G, Rupp S, Storz P, Pfizenmaier K, et al: Protein kinase C (PKC)eta-
mediated PKC mu activation modulates ERK and JNK signal pathways. J
Biol Chem 2002, 277:6490-6.
29. Katoch SS, Su X, Moreland RS: Ca(2+)- and protein kinase C-dependent
stimulation of mitogen-activated protein kinase in detergent-skinned
vascular smooth muscle. J Cell Physiol 1999, 179:208-17.
30. Karin M: The regulation of AP-1 activity by mitogen-activated protein
kinases. J Biol Chem 1995, 270:16483-6.
31. Shen Q, Uray IP, Li Y, Krisko TI, Strecker TE, Kim HT, Brown PH: The AP-1
transcription factor regulates breast cancer cell growth via cyclins and
E2F factors. Oncogene 2008, 27:366-77.
32. Herber B, Truss M, Beato M, Muller R: Inducible regulatory elements in the
human cyclin D1 promoter. Oncogene 1994, 9:1295-304.
33. Gan L, Liu P, Lu H, Chen S, Yang J, McCarthy JB, Knudsen KE, Huang H:
Cyclin D1 promotes anchorage-independent cell survival by inhibiting
FOXO-mediated anoikis. Cell Death Differ 2009, 16(10):1408-17, Epub 2009
Jul 3.
34. Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S,
Holmberg L, Bergh J: Overexpression of cyclin E protein is associated
with specific mutation types in the p53 gene and poor survival in
human breast cancer. Carcinogenesis 2004, 25:375-80.
35. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I,
Loh DY: Mice lacking p27(Kip1) display increased body size, multiple
organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996,
85:707-20.
36. Liotta LA, Kohn E: Anoikis: cancer and the homeless cell. Nature 2004,
430:973-4.
37. Yang JY, Hung MC: A new fork for clinical application: targeting forkhead
transcription factors in cancer. Clin Cancer Res 2009, 15:752-7.
38. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC,
Chang CJ, Huang WC, et al: ERK promotes tumorigenesis by inhibiting
FOXO3a via MDM2-mediated degradation. Nat Cell Biol 2008, 10:138-48.
39. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P: Activation of ERK1/2
protects melanoma cells from TRAIL-induced apoptosis by inhibiting
Smac/DIABLO release from mitochondria. Oncogene 2003, 22:2869-81.
40. Kohno M, Pouyssegur J: Pharmacological inhibitors of the ERK signaling
pathway: application as anticancer drugs. Prog Cell Cycle Res 2003,
5:219-24.
41. Montagut C, Settleman J: Targeting the RAF-MEK-ERK pathway in cancer
therapy. Cancer Lett 2009, 283:125-34.
42. Bardeesy N, DePinho RA: Pancreatic cancer biology and genetics. Nat Rev
Cancer 2002, 2:897-909.
43. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ: Understanding Ras: ‘it ain’t
over ‘til it’s over’. Trends Cell Biol 2000, 10:147-54.
44. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M,
Goodman SN, Sohn TA, Hruban RH, Yeo CJ, et al: Tumor-suppressive
pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-4.
45. Trerotola M, Rathore S, Goel HL, Li J, Alberti S, Piantelli M, Adams D,
Jiang Z, Languino LR: CD133, Trop-2 and alpha2beta1 integrin surface
receptors as markers of putative human prostate cancer stem cells. Am J
Transl Res 2:135-44.
46. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr,
Schabel FM Jr: Induction and chemotherapeutic response of two
transplantable ductal adenocarcinomas of the pancreas in C57BL/6
mice. Cancer Res 1984, 44:717-26.
47. Furukawa T, Duguid WP, Rosenberg L, Viallet J, Galloway DA, Tsao MS:
Long-term culture and immortalization of epithelial cells from normal
adult human pancreatic ducts transfected by the E6E7 gene of human
papilloma virus 16. Am J Pathol 1996, 148:1763-70.
doi:10.1186/1476-4598-9-253
Cite this article as: Cubas et al.: Trop2 expression contributes to tumor
pathogenesis by activating the ERK MAPK pathway. Molecular Cancer
2010 9:253.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cubas et al. Molecular Cancer 2010, 9:253
http://www.molecular-cancer.com/content/9/1/253
Page 13 of 13